As of Thursday close, Sabra Health Care REIT Inc.’s (NASDAQ:SBRA) stock was down -$0.19, moving down -1.58 percent to $11.81. The average number of shares traded per day over the past five days has been 2,265,080 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.62 fall in that time frame. In the last twenty days, the average volume was 2,127,660, while in the previous 50 days, it was 2,160,200.
Since last month, SBRA stock retreated -8.09%. Shares of the company fell to $11.80 on 08/17/23, the lowest level in the past month. A 52-week high of $15.99 was reached on 02/02/23 after having rallying from a 52-week low of $10.08. Since the beginning of this year, SBRA’s stock price has dropped by -4.99% or -$0.62, and marked a new high 11 times. However, the stock has declined by -26.16% since its 52-week high.
Valuation Metrics
The stock’s beta is 1.30. Besides these, the trailing price-to-sales (P/S) ratio of 4.26, the price-to-book (PB) ratio of 0.93, and the price-to-cash flow ratio of 13.17 may also be considered.
The latest dividend of $0.30 per share was paid out, remained unchanged from last year’s $0.30. On Wednesday May 6 2020, a $0.15 dividend decrease was announced.
Financial Health
According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.82, and the total debt-to-equity ratio was 0.82. On the profitability front, the trailing twelve-month gross margin is 74.00% percent. In the year ended June 29, operating margins totaled 1.30%. Based on annual data, SBRA earned $140.66 million in gross profit and brought in $624.81 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 0.60%. Return on equity (ROE) for the past 12 months was -4.00%.
In Sabra Health Care REIT Inc.’s quarter-end financial report for June 29, it reported total debt of $48.27 million. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. SBRA’s revenue rose 3.23% to $161.32 million during the quarter, while net income inched up to $161.17 million. While analysts expected Sabra Health Care REIT Inc. to report $0.1 quarterly earnings, the actual figure was $0.09 per share. During the quarter, the company generated $102.47 million in EBITDA. The value of shareholders’ equity is $231.22 million.
Technical Picture
This quick technical analysis looks at Sabra Health Care REIT Inc.’s (SBRA) price momentum. With a historical volatility rate of 23.53%, the RSI 9-day stood at 22.56% on 17 August.
With respect to its five-day moving average, the current Sabra Health Care REIT Inc. price is down by -4.99% percent or -$0.62. At present, SBRA shares trade -9.92% below its 20-day simple moving average and +12.91% percent above its 100-day simple moving average. However, the stock is currently trading approximately +1.11% above its SMA50 and -14.05% below its SMA200.
Stochastic coefficient K was 2.84% and Stochastic coefficient D was 10.51%, while ATR was 0.29. Given the Stochastic reading of 0.68% for the 14-day period, the RSI (14) reading has been calculated as 31.67%. As of today, the MACD Oscillator reading stands at -0.40, while the 14-day reading stands at -0.54.
Analyst Ratings
BofA Securities upgraded its rating on Sabra Health Care REIT Inc. (NASDAQ: SBRA) to a Neutral in a note to investors on August 11, 2023. The analysts firm previously had an Underperform rating on the stock.Sabra Health Care REIT Inc. (SBRA) has been rated Hold by analysts. According to 1 brokerage firm, SBRA is a sell, and 10 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Sabra Health Care REIT Inc. stock as buy, with 4 recommending it as overweight.
With a median target price of $13.00, the current consensus forecast for the stock is $11.00 – $15.00. Based on these forecasts, analysts predict Sabra Health Care REIT Inc. (SBRA) will achieve an average price target of $13.13.
